content: SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  
  
  Date  of  Report  (Date of earliest event reported)   DECEMBER 22, 1995 
  
                                      ENZON, INC.
  
                    (Exact  name  of  registrant  as  specified  in its charter)
  
  
  
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
  
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  
  
  Registrant's telephone number, including area code    (908) 980-4500
  
  
  
  
       (Former name or former address, if changed since last report)
  
  
  
  ITEM 5.  OTHER EVENTS
  
       Enzon, Inc. ("Enzon" or the "Company") has granted Rhone-Poulenc Rorer
  Inc. ("RPR") a worldwide, non-exclusive license to use Enzon's Single-Chain
  Antigen-Binding ("SCA") protein technology for intracellular expression  of
  SCA  proteins  and  for  targeted  vectors  in  the  field of cell and gene
  therapy.   RPR  Gencell,  the  cell and gene therapy division  of  RPR,  is
  planning to apply this technology  to  its in vivo and ex vivo gene therapy
  programs in cancer, cardiovascular disease  and immunology.  RPR paid Enzon
  a  $1,000,000  license  fee  and  will make additional  payments  upon  the
  achievement of specified product development milestones.  RPR will also pay
  Enzon  a  royalty  based upon sales of  products  incorporating  the  Enzon
  technology.
  
  
  
  
  <PAGE>
  
                              SIGNATURES
  
  
       Pursuant to the  requirements  of the Securities Exchange Act of 1934,
  
  the Registrant has duly caused this report  to  be  signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  
  
  
  Dated:  February 7, 1996
  
  
  
  
                                                ENZON, INC.
                                               (Registrant)
  
                                     By:   /S/ KENNETH J. ZUERBLIS
                                           Kenneth J. Zuerblis
                                           Vice President, Finance
                                           and Chief Financial Officer
metadata_documents: [{"type": "8-K", "sequence": "1", "secsgml_size_bytes": 2388}]
metadata_filer: {"company-data": {"conformed-name": "ENZON INC", "cik": "0000727510", "assigned-sic": "2836", "irs-number": "222372868", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-12957", "film-number": "96513103"}, "business-address": {"street1": "40 KINGSBRIDGE RD", "city": "PISCATAWAY", "state": "NJ", "zip": "08854", "phone": "9089804500"}, "mail-address": {"street1": "C/O ROSS & HARDIES", "street2": "65 EAST 55TH STREET", "city": "NEW YORK", "state": "NY", "zip": "10022-3219"}}
text: SECURITIES AND EXCHANGE COMMISSION
  
                          WASHINGTON, D.C.  20549
  
                                 FORM 8-K
  
                              CURRENT REPORT
  
  PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
  
  Date  of  Report  (Date of earliest event reported)   DECEMBER 22, 1995 
  
                                      ENZON, INC.
  
                    (Exact  name  of  registrant  as  specified  in its charter)
  
         DELAWARE                    0-12957              22-237286
     (State or other jurisdiction   (Commission          (IRS Employer
         of incorporation)         File Number)          Identification)
  
          20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
            (Address of principal executive offices)       (Zip Code)
  
  Registrant's telephone number, including area code    (908) 980-4500
  
       (Former name or former address, if changed since last report)
  
  ITEM 5.  OTHER EVENTS
  
       Enzon, Inc. ("Enzon" or the "Company") has granted Rhone-Poulenc Rorer
  Inc. ("RPR") a worldwide, non-exclusive license to use Enzon's Single-Chain
  Antigen-Binding ("SCA") protein technology for intracellular expression  of
  SCA  proteins  and  for  targeted  vectors  in  the  field of cell and gene
  therapy.   RPR  Gencell,  the  cell and gene therapy division  of  RPR,  is
  planning to apply this technology  to  its in vivo and ex vivo gene therapy
  programs in cancer, cardiovascular disease  and immunology.  RPR paid Enzon
  a  $1,000,000  license  fee  and  will make additional  payments  upon  the
  achievement of specified product development milestones.  RPR will also pay
  Enzon  a  royalty  based upon sales of  products  incorporating  the  Enzon
  technology.
  SIGNATURES
  
       Pursuant to the  requirements  of the Securities Exchange Act of 1934,
  
  the Registrant has duly caused this report  to  be  signed on its behalf by
  
  the undersigned hereunto duly authorized.
  
  Dated:  February 7, 1996
  
                                                ENZON, INC.
                                               (Registrant)
  
                                     By:   /S/ KENNETH J. ZUERBLIS
                                           Kenneth J. Zuerblis
                                           Vice President, Finance
                                           and Chief Financial Officer